Figures & data
Figure 1. Budget impact model structure. Model structure is based on current modeling standards for the budget impact of pharmaceutical products.
![Figure 1. Budget impact model structure. Model structure is based on current modeling standards for the budget impact of pharmaceutical products.](/cms/asset/98a8de1f-7a26-4743-a6e3-060d5bcc0a2a/ijme_a_749788_f0001_b.jpg)
Table 1. Target population inputs.
Table 2. Market share inputs.
Table 3. Pharmacy cost inputs.
Table 4. Medical cost inputs.
Figure 3. One-way sensitivity analyses. aEverolimus plus exemestane market share: 20% market share as the second treatment option after letrozole or anastrozole failure.
![Figure 3. One-way sensitivity analyses. aEverolimus plus exemestane market share: 20% market share as the second treatment option after letrozole or anastrozole failure.](/cms/asset/12fda129-319e-44a2-ab33-158c85a43275/ijme_a_749788_f0003_b.jpg)
Figure 4. Two-way sensitivity analyses. (a) Target population size and everolimus cost. (b) Target population size and medical cost.
![Figure 4. Two-way sensitivity analyses. (a) Target population size and everolimus cost. (b) Target population size and medical cost.](/cms/asset/388f03a5-7816-4925-9535-6576fe67270b/ijme_a_749788_f0004_b.jpg)